Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England’s Real-World Evidence Framework Coming Soon

HTA Body Says RWE Will Reduce Uncertainties & Improve Guidance

Executive Summary

England’s health technology appraisal body, NICE, will publish a framework that will help it deliver on its ambition to use real-world evidence to close knowledge gaps and improve technology evaluations.

You may also be interested in...



UK: RWD At Center Of NICE Five-Year Strategy

NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.

German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy

In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel